全文获取类型
收费全文 | 52篇 |
免费 | 4篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 15篇 |
内科学 | 6篇 |
皮肤病学 | 1篇 |
神经病学 | 1篇 |
特种医学 | 1篇 |
外科学 | 8篇 |
预防医学 | 1篇 |
药学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2020年 | 1篇 |
2018年 | 1篇 |
2015年 | 2篇 |
2014年 | 3篇 |
2012年 | 4篇 |
2011年 | 5篇 |
2010年 | 2篇 |
2009年 | 2篇 |
2008年 | 2篇 |
2007年 | 5篇 |
2006年 | 2篇 |
2005年 | 3篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 4篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有56条查询结果,搜索用时 15 毫秒
1.
Teresa Sampedro Gimeno Fernando Moreno Antón Sara López-Tarruella Cobo José Luis González Larriba Vicente Furio Bacete Eduardo Díaz-Rubio García 《Clinical & translational oncology》2006,8(1):57-59
Malignant melanoma is the most rapidly increasing cancer in the world. Metastatic disease occurs in 20% of patients, and prognosis
in these cases is poor. We report the case of a woman who presented breast metastasis as the first sign of recurrence of a
melanoma. 相似文献
2.
3.
4.
Larriba JL Espinosa E Carbonero IG García-Donas J López M Meana A Puente J Bellmunt J 《Cancer metastasis reviews》2012,31(Z1):11-17
Few types of cancer have had their treatment evolve as rapidly as metastatic renal cell carcinoma (mRCC). Since 2005, six new targeted therapies with proven efficacy have been approved for the treatment of mRCC. The downside is that our knowledge about the mechanisms of action of these therapies and the intrinsic and extrinsic mechanism of resistance has not evolved equally fast, and many questions remain unanswered. The only approved agent to date in the European Union for patients who progress on sunitinib or sorafenib is everolimus. The results of the phase III trial comparing axitinib vs. sorafenib after failure on sunitinib, bevacizumab, temsirolimus, or cytokines have recently been published, and axitinib has recently been licensed by the Food and Drugs Administration. Other phase III trials that are being conducted include a comparison between everolimus plus bevacizumab and everolimus after failure on tyrosine kinase inhibitors, and between temsirolimus and sorafenib after failure on sunitinib. In this article, we will review the available evidence from clinical studies on sequential therapy for mRCC, including those that are still in progress. In addition, information on the mechanism of resistance or tolerance to first-line therapy, recommendations of the main practice guidelines for second-line treatment, potential therapies for third or successive treatment lines, and the major reasons why patients who progress may benefit from a change of mechanism of action will also be discussed. 相似文献
5.
Yolanda Larriba Cristina Rueda Miguel A. Fernández Shyamal D. Peddada 《Statistics in medicine》2020,39(3):265-278
This paper is motivated by applications in oscillatory systems where researchers are typically interested in discovering components of those systems that display rhythmic temporal patterns. The contributions of this paper are twofold. First, a methodology is developed based on a circular signal plus error model that is defined using order restrictions. This mathematical formulation of rhythmicity is simple, easily interpretable and very flexible, with the latter property derived from the nonparametric formulation of the signal. Second, we address various commonly encountered problems in the analysis of oscillatory systems data. Specifically, we propose a methodology for (a) detecting rhythmic signals in an oscillatory system and (b) estimating the unknown sampling time that occurs when tissues are obtained from subjects whose time of death is unknown. The proposed methodology is computationally efficient, outperforms the existing methods, and is broadly applicable to address a wide range of questions related to oscillatory systems. 相似文献
6.
Theresa Larriba Harboe Hans Eiberg Peder Kern Bent Ejlertsen Lotte Nedergaard Vera Timmermans-Wielenga Inge-Merete Nielsen Marie Luise Bisgaard 《Familial cancer》2009,8(4):413-419
Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1
and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36–92% life time risk of
breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this
study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from
Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency
was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously
isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever
to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine
ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients
(33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known
to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for
the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths. 相似文献
7.
The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells 总被引:1,自引:0,他引:1
8.
9.
Casals T Bassas L Egozcue S Ramos MD Giménez J Segura A Garcia F Carrera M Larriba S Sarquella J Estivill X 《Human reproduction (Oxford, England)》2000,15(7):1476-1483
Congenital absence of the vas deferens (CAVD) is a heterogeneous disorder, largely due to mutations in the cystic fibrosis (CFTR) gene. Patients with unilateral absence of the vas deferens (CUAVD) and patients with CAVD in association with renal agenesis appear to have a different aetiology to those with isolated CAVD. We have studied 134 Spanish CAVD patients [110 congenital bilateral absence of the vas deferens (CBAVD) and 24 CUAVD], 16 of whom (six CBAVD, 10 CUAVD) had additional renal anomalies. Forty-two different CFTR mutations were identified, seven of them being novel. Some 45% of the CFTR mutations were specific to CAVD, and were not found in patients with cystic fibrosis or in the general Spanish population. CFTR mutations were detected in 85% of CBAVD patients and in 38% of those with CUAVD. Among those patients with renal anomalies, 31% carried one CFTR mutation. Anomalies in seminal vesicles and ejaculatory ducts were common in patients with CAVD. The prevalence of cryptorchidism and inguinal hernia appeared to be increased in CAVD patients, as well as nasal pathology and frequent respiratory infections. This study confirms the molecular heterogeneity of CFTR mutations in CAVD, and emphasizes the importance of an extensive CFTR analysis in these patients. In contrast with previous studies, this report suggests that CFTR might have a role in urogenital anomalies. 相似文献
10.